2 articles for “Antibody-based Therapeutics”

Research ArticleOpen accessPhrase in the titleMonoclonal Antibody-Based Therapeutics for Melioidosis and GlandersHyung-Yong Kim, Alexander Stojadinovic, Peter J. Weina et al.Problem statement: Burkholderia Pseudomallei (BP) and B. Mallei (BM) were two closely related pathogenic gram-negative bacteria. They were the causative agents of melioidosis and glanders, respectively and are recognized by CDC as category B select agents. Significant efforts had been devoted to developing the diagnostic and therapeutic measures against these two pathogens. Monoclonal antibody-based therapeutic was a promising targeted therapy … …American Journal of Immunology, Vol. 7, Issue 3 · 23 Dec 2011 · 8,982 accessesView PDF Cite

Research NotesOpen accessIn the keywordsIndividualizing Periods of Commercial Exclusivity to Control Pricing for Drugs and BiologicsCallie M. Blase, Brandon K. Rouault, Maia B. Zoller et al.The pricing for immunologic agents and antibody-based therapeutics has increased precipitously in recent years. Among the key contributors to price hikes is the static practice of granting commercial exclusivity to innovator drugs and biologics. Herein, we present a mechanism for individualizing periods of commercial exclusivity to control pricing for drugs and biologics. …American Journal of Immunology, Vol. 15, Issue 1 · 13 Sep 2019 · 7,014 accessesView PDF Cite